drugset / Trial / NCT06788964

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

NCT06788964

Phase 2 Recruiting 29 enrolled University of Utah ADC Therapeutics S.A. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.

Timeline

Start
2025-08-25
Primary completion
2027-03
Completion
2030-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Loncastuximab Tesirine Other / unclassified Intravenous
Subject Rituximab Monoclonal antibody Intravenous

Indications